首页>
外文期刊>Prescrire international
>Fostemsavir crukobia0) in multidrug-resistant HIV-1 infection: An option of last resort, with cardiac, cutaneous and muscular harms
【24h】
Fostemsavir crukobia0) in multidrug-resistant HIV-1 infection: An option of last resort, with cardiac, cutaneous and muscular harms
展开▼
机译：Fostemsavir crukobia0) in multidrug-resistant HIV-1 infection: An option of last resort, with cardiac, cutaneous and muscular harms
According to the scarce data available as of late 2021, when an HIV-1-infected patient has run out of treatment options, adding fostemsavir to "optimised" antiretroviral therapy seems to result in greater antiviral activity. The addition of fostemsavir probably contributed to the undetectable viral load obtained in 40% to 60% of patients after 96 weeks of treatment. Fostemsavir's main known adverse effects are gastrointestinal disorders, QT prolongation, skin disorders and muscle disorders. Many uncertainties remain due to the lack of long-term data, and because the drug was evaluated in so few patients. Despite the limitations of fostemsavir's evaluation, it is useful to have another antiretroviral drug with some degree of efficacy for patients in the difficult clinical situation of having exhausted all other treatment options. Oral fostemsavir is an alternative to ibalizumab, which is administered intravenously.
展开▼
